期刊文献+

尿苷二磷酸葡萄糖醛酸转移酶1A6基因多态性与抗结核药致肝损害的相关性 被引量:11

Relationship between the polymorphisms of UGT1A6 genes and anti-tuberculosis drug induced hepatic-injury
原文传递
导出
摘要 目的探讨尿营二磷酸葡萄糖醛酸转移酶1A6(UGT1A6)基因多态性与中国唐山地区结核患者抗结核药致肝损害的相关性。方法采用病例对照研究,以抗结核治疗导致肝损害患者202例为病例组,无肝损害者239例为对照组,收集环境因素暴露情况及静脉血。UGT1A6基因多态性分析采用聚合酶链反应限制性片段长度多态方法,利用HhaⅠ、DpnⅡ和NsiⅠ内切酶分析其基因多态性,以SPSS13.0软件对各危险因素进行单因素和多因素非条件Logistic回归分析。结果UGT1A6的19T/G、308C/A和541A/G多态性位点均存在3种基因型,UGT1A619T/T、UGT1A619T/G和UGT1A6—19G/G在病例组和对照组的频率分别为51.5%、39.6%、8.9%和71.1%、25.5%、3.3%;UGT1A6—308C/C、UGT1A6308C/A和UGT1A6—308A/A在病例组和对照组的频率分别为52.0%、40.6%、7.4%和79.1%、19.2%、1.7%;UGT1A6541AA、UGT1A6—541A/G和UGT1A6541G/G在病例组和对照组的频率分别为57.9%、33.7%、8.4%和79.5%、19.2%、1.3%,两组问差异均有统计学意义(x^2值分别为17.956、37.385和24.095,P值均〈0.01)。单因素和多凶素分析均显示UGT1A619T/G、308C/A、541A/G3个位点基因多态性与抗结核药致肝损害的发生有关(P值均〈0.05)。结论UGT1A6基因多态性可能与汉族人抗结核药致肝损害的发病有关,且各基因型存在相互作用。 Objective To investigate the relationship between the polymorphisms of UGT1A6 genes and anti-tuberculosis drug induced hepatic-injury (ADIH). Methods 202 cases and 239 controls were collected and a case-control study was conducted. Information on related risk factors of tuberculosis was collected. The genotypes of UGT 1A6-19T/G, UGT 1A6-308C/A and UGT 1 A6-541A/G genetic polymorphisms were detected by polymerase chain reaction and restriction fragment length polymorphism technique (PCR- RFLP) in patients received anti-tuberculosis therapy. The Hha I, Dpn II and Nsi I enzyme were employed. Univariate and multivariate conditional logistic analyses were conducted using SPSS13.0 for windows software. Results The allele frequency ofgene UGTIA6-19T/T, UGT1A6-19T/G, UGTIA6-19G/G, GT1A6-308C/ C, UGT1A6-308C/A, UGTI A6-308A/A, UGT1 A6-541AA, UGT1A6-541A/G and UGT1A6-541G/G in ADIH group were 51.5%, 39.6%, 8.9%, 52.0%, 40.6%, 7.4%, 57.9%, 33.7%, 8.4% and 71.1%, 25.5%, 3.3%, 79.1%, 19.2%, 1.7%, 79.5%, 19.2%, 1.3% in control group, respectively. Univariate analysis demonstrated that the frequency of UGT1A6-19T/G, UGT1A6-308C/A and UGT1A6-541A/G genotype in cases were significantly higher than that in controls (P 〈 0.05). Conclusion A positive association is found between UGT1A6 genotype and the occurrence of ADIH. The synergetic effect is proved on susceptibility to pulmonary tuberculosis between UGT1A6 mutant genotypes.
出处 《中华肝脏病杂志》 CAS CSCD 北大核心 2011年第3期201-204,共4页 Chinese Journal of Hepatology
基金 唐山市重点实验室项目(08150201A-1-8)
关键词 结核 抗结核药 尿苷二磷酸葡萄糖醛酸转移酶1A6 多态性 基因 肝损害 Tuberculosis, pulmonary Antitubercular agents UDP-glucuronosyltransferase 1A6 Polymorphism, genes Hepatic injures
  • 相关文献

参考文献8

  • 1Nagar S, Zalatoris JJ, Blanchard RL. Human UGT1A6 pharmacogenetics: identification of a novel SNP, characterization of allele frequencies and functional analysis of recombinant allozymes in human liver tissue and in cultured cells. Pharmacogenetics, 2004, 14: 487-499.
  • 2Polonikov AV, Ivanov VP, Solodilova MA. Genetic variation of genes for xenobiotic-metabolizing enzymes and risk of bronchial asthma: the importance of gene-gene and gene-environment interactions for disease susceptibility. J Hum Genet, 2009, 54: 440-449.
  • 3Gagn6 JF, Montminy V, Belanger P, et al. Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol, 2002, 62: 608-617.
  • 4Lampe JW. Diet, genetic polymorphisms, detoxification, and health risks. Altem Ther Health Med, 2007, 13: S108-111.
  • 5Saeki M, Saito Y, Jinno H, et al. Genetic polymorphisms of UGT1A6 in a Japanese population. Drug Metab Pharmacokinet, 2005, 20: 85-90.
  • 6程书权.抗结核药物致肝损害172例临床分析[J].中华肝脏病杂志,2004,12(9):571-571. 被引量:31
  • 7Iida K, Mimura J, Itoh K, et al. Suppression of AhR signaling pathway is associated with the down-regulation of UDPglucuronosyltransferases during BBN-induced urinary bladder carcinogenesis in mice. J Biochem, 2010, 147: 353-360.
  • 8Ciotti M, Marrone A, Potter C, et al. Genetic polymorphism in the human UGT1A6 (planar phenol) UDP-glucuronosyltransferase: pharmacological implications. Pharmacogenetics, 1997, 7: 485-495.

二级参考文献5

  • 1Turktas H, Unsal M, Tulek N, et al. Hepatotoxicity of antituberculosis therapy (rifampicin, isoniazidand and pyrazinamide) or viral hepatitis.Tuber Lung Dis, 1994, 75: 58-60.
  • 2Jasmer RM, Daley CL. Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe? Am J Respir Crit Care Med,2003, 167: 809-810.
  • 3Kaplowitz N. Drug-induced liver disorders: implications for drug development and regulation. Drug Saf, 2001, 24: 483-490.
  • 4Kunimoto D, Warman A, Beckon A, et al. Severe hepatotoxicity associated with rifampin-pyrazinamide preventative therapy requiring transplantation in an individual at low risk for hepatotoxicity. Clin Infect Dis, 2003, 36: 158-161.
  • 5Castro KG, Jereb JA, Koppaka VR, et al. Fatal liver injury associated with rifampin-pyrazinamide treatment of latent tuberculosis infection. Chest, 2003, 123: 967.

共引文献30

同被引文献110

引证文献11

二级引证文献131

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部